Company profile RYTM

Rhythm Pharmaceuticals Inc.
rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.
Quarter analysis & expected interest

There is not enough data for Rhythm Pharmaceuticals near me to provide analysis

Correlation between past revenue and Rhythm Pharmaceuticals near me search interest

There is not enough data for Rhythm Pharmaceuticals near me to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Rhythm Pharmaceuticals near me to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IMCIVREE therapy to provide analysis

Correlation between past revenue and IMCIVREE therapy search interest

There is not enough data for IMCIVREE therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IMCIVREE therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 21:54:22.

After 38 days of this quarter the interest is at 24.0. Based on that we can calculate that during remaining 53 days it will total up to 57.0.
Rhythm Pharmaceuticals stock expected interest is significantly higher compared to same quarter last year (+216.7%) but lower than previous quarter (-69.4%).

YearQ1Q2Q3Q4
201938
75
97.4% QoQ
22
-70.7% QoQ
154
600.0% QoQ
2020 193
407.9% YoY 25.3% QoQ
135
80.0% YoY -30.1% QoQ
70
218.2% YoY -48.1% QoQ
223
44.8% YoY 218.6% QoQ
2021 150
-22.3% YoY -32.7% QoQ
55
-59.3% YoY -63.3% QoQ
57
-18.6% YoY 3.6% QoQ
95
-57.4% YoY 66.7% QoQ
2022 153
2.0% YoY 61.1% QoQ
85
54.5% YoY -44.4% QoQ
226
296.5% YoY 165.9% QoQ
48
-49.5% YoY -78.8% QoQ
2023 18
-88.2% YoY -62.5% QoQ
124
45.9% YoY 588.9% QoQ
112
-50.4% YoY -9.7% QoQ
186
287.5% YoY 66.1% QoQ
2024 24
33.3% YoY -87.1% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Rhythm Pharmaceuticals stock search interestLast update: February 07 2024 21:54:22.
Correlation coefficient between keyword and revenue is -0.16
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 21:54:25.

The average 5 years interest of Rhythm Pharmaceuticals stock was 8.63 per week.
The last year interest of Rhythm Pharmaceuticals stock compared to the last 5 years has changed by 3.36%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 42.72%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for melanocortin-4 receptor deficiency obesity to provide analysis

Correlation between past revenue and melanocortin-4 receptor deficiency obesity search interest

There is not enough data for melanocortin-4 receptor deficiency obesity to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for melanocortin-4 receptor deficiency obesity to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 21:54:29.

After 38 days of this quarter the interest is at 122.0. Based on that we can calculate that during remaining 53 days it will total up to 292.0.
Bardet-Biedl syndrome expected interest is significantly higher compared to same quarter last year (+78.0%) but similar to previous quarter.

YearQ1Q2Q3Q4
2019172
133
-22.7% QoQ
256
92.5% QoQ
93
-63.7% QoQ
2020 167
-2.9% YoY 79.6% QoQ
207
55.6% YoY 24.0% QoQ
114
-55.5% YoY -44.9% QoQ
127
36.6% YoY 11.4% QoQ
2021 277
65.9% YoY 118.1% QoQ
183
-11.6% YoY -33.9% QoQ
165
44.7% YoY -9.8% QoQ
238
87.4% YoY 44.2% QoQ
2022 242
-12.6% YoY 1.7% QoQ
307
67.8% YoY 26.9% QoQ
317
92.1% YoY 3.3% QoQ
307
29.0% YoY -3.2% QoQ
2023 164
-32.2% YoY -46.6% QoQ
414
34.9% YoY 152.4% QoQ
145
-54.3% YoY -65.0% QoQ
382
24.4% YoY 163.4% QoQ
2024 122
-25.6% YoY -68.1% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Bardet-Biedl syndrome search interestLast update: February 07 2024 21:54:28.
Correlation coefficient between keyword and revenue is 0.6
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 21:54:29.

The average 5 years interest of Bardet-Biedl syndrome was 17.43 per week.
The last year interest of Bardet-Biedl syndrome compared to the last 5 years has changed by 25.53%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 46.06%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 21:54:32.

After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0.
Alström syndrome expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201993
0
-100.0% QoQ
99
inf% QoQ
57
-42.4% QoQ
2020 132
41.9% YoY 131.6% QoQ
42
inf% YoY -68.2% QoQ
140
41.4% YoY 233.3% QoQ
62
8.8% YoY -55.7% QoQ
2021 128
-3.0% YoY 106.5% QoQ
34
-19.0% YoY -73.4% QoQ
40
-71.4% YoY 17.6% QoQ
119
91.9% YoY 197.5% QoQ
2022 68
-46.9% YoY -42.9% QoQ
142
317.6% YoY 108.8% QoQ
171
327.5% YoY 20.4% QoQ
50
-58.0% YoY -70.8% QoQ
2023 104
52.9% YoY 108.0% QoQ
0
-100.0% YoY -100.0% QoQ
118
-31.0% YoY inf% QoQ
71
42.0% YoY -39.8% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Alström syndrome search interestLast update: February 07 2024 21:54:32.
Correlation coefficient between keyword and revenue is -0.29
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 21:54:32.

The average 5 years interest of Alström syndrome was 6.42 per week.
The last year interest of Alström syndrome compared to the last 5 years has changed by -35.67%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -23.52%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for MC4R disorders to provide analysis

Correlation between past revenue and MC4R disorders search interest

There is not enough data for MC4R disorders to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for MC4R disorders to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for setmelanotide clinical trials to provide analysis

Correlation between past revenue and setmelanotide clinical trials search interest

There is not enough data for setmelanotide clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for setmelanotide clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for rare genetic diseases of obesity to provide analysis

Correlation between past revenue and rare genetic diseases of obesity search interest

There is not enough data for rare genetic diseases of obesity to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for rare genetic diseases of obesity to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for RYTM
Earnings date: 2024-02-22 After close
Company name: Rhythm Pharmaceuticals Inc.
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-12T12:00:00Z

GlobeNewswire
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

2026-05-07T22:23:45Z

Analyst Upgrades
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

2026-05-06T18:04:59Z

Analyst Upgrades
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

2026-05-06T15:54:42Z

Analyst Upgrades
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $137

2026-05-06T13:27:16Z

Analyst Upgrades
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $144

2026-05-06T12:00:00Z

GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

2026-05-05T11:00:00Z

GlobeNewswire
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

2026-05-04T12:00:00Z

GlobeNewswire
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

2026-05-01T10:55:00Z

GlobeNewswire
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

2026-04-09T12:00:00Z

GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

2026-04-03T13:00:00Z

GlobeNewswire
Rhythm Pharmaceuticals Announces Changes to Board of Directors

2026-03-26T13:01:56Z

GlobeNewswire
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

2026-03-23T11:06:08Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $105

2026-03-20T19:19:46Z

Analyst Upgrades
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $142

2026-03-20T17:14:05Z

Analyst Upgrades
B of A Securities Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $149